The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients
One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemi...
Saved in:
Published in | Ecancermedicalscience Vol. 15; p. 1180 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Cancer Intelligence
03.02.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1754-6605 1754-6605 |
DOI | 10.3332/ecancer.2021.1180 |
Cover
Loading…
Abstract | One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths. |
---|---|
AbstractList | One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic.
There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease.
The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths. One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths. One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths. |
Author | Haire, Kate Aggarwal, Ajay Dodkins, Joanna Rigg, Anne Roberts, Graham Purushotham, Arnie Harvey-Jones, Elizabeth Sullivan, Richard Han, Lu Twinn, Claire Pramesh, Conjeevaram Ranganathan, Priya |
Author_xml | – sequence: 1 givenname: Arnie surname: Purushotham fullname: Purushotham, Arnie – sequence: 2 givenname: Graham surname: Roberts fullname: Roberts, Graham – sequence: 3 givenname: Kate surname: Haire fullname: Haire, Kate – sequence: 4 givenname: Joanna surname: Dodkins fullname: Dodkins, Joanna – sequence: 5 givenname: Elizabeth surname: Harvey-Jones fullname: Harvey-Jones, Elizabeth – sequence: 6 givenname: Lu surname: Han fullname: Han, Lu – sequence: 7 givenname: Anne surname: Rigg fullname: Rigg, Anne – sequence: 8 givenname: Claire surname: Twinn fullname: Twinn, Claire – sequence: 9 givenname: Conjeevaram surname: Pramesh fullname: Pramesh, Conjeevaram – sequence: 10 givenname: Priya surname: Ranganathan fullname: Ranganathan, Priya – sequence: 11 givenname: Richard surname: Sullivan fullname: Sullivan, Richard – sequence: 12 givenname: Ajay surname: Aggarwal fullname: Aggarwal, Ajay |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33777173$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kctKxDAYhYMo3h_AjXSpi465NE27EUS8geBG1yHNxYm2SU06ijsfQ1_PJzF1RlHBVcKfc74T_rMBlp13GoAdBCeEEHygpXBShwmGGE0QquASWEeMFnlZQrr8474GNmK8g7BENaarYI0QxhhiZB3011Od2a4Xcsi8yZwYrHeizVJS3k9F6ITUs8HKNLJu0OFRu1ERs733l9fWy3vln1x8f3nbz7zLhgTrg45J9AkakfM_Zn0apHHcAitGtFFvL85NcHN6cn18nl9enV0cH13mktT1kDOqKgVxiSQkVDOJK8OQokWFG2NqaZQpdIFgVVOklGhK0yhYNbJiqqQUU0I2weGc28-aTiuZsoNoeR9sJ8Iz98Ly3y_OTvmtf-SsrlhR4wTYWwCCf5jpOPDORqnbVjjtZ5FjCksKaQ3HrN2fWd8hX2tOAjYXyOBjDNpwaecbStG25QjysVC-KJSPhfKx0OREf5xf8P89H96Wqq8 |
CitedBy_id | crossref_primary_10_1016_j_jtocrr_2023_100560 crossref_primary_10_1038_s41416_024_02703_w crossref_primary_10_1111_bju_15699 crossref_primary_10_1089_hs_2021_0084 crossref_primary_10_1111_bju_16305 crossref_primary_10_1016_j_ciresp_2022_02_001 crossref_primary_10_1038_s41416_024_02931_0 crossref_primary_10_1016_j_ijdrr_2024_105140 crossref_primary_10_1038_s41416_024_02596_9 crossref_primary_10_1136_bmjonc_2022_000012 crossref_primary_10_1016_j_cireng_2022_02_017 crossref_primary_10_2478_inmed_2024_0274 crossref_primary_10_3390_cancers15041273 crossref_primary_10_1038_s41416_022_01909_0 crossref_primary_10_3390_cancers14020266 crossref_primary_10_1016_j_ejca_2021_04_019 crossref_primary_10_6004_jnccn_2021_7114 crossref_primary_10_2217_fon_2021_1329 crossref_primary_10_1016_S1470_2045_22_00754_9 crossref_primary_10_3390_cancers15194700 crossref_primary_10_3389_fpubh_2022_988736 crossref_primary_10_1038_s41416_022_01830_6 crossref_primary_10_1186_s12885_023_11795_1 crossref_primary_10_1007_s00520_023_07944_8 crossref_primary_10_1136_spcare_2023_004310 crossref_primary_10_1136_bmjopen_2021_059374 crossref_primary_10_1186_s12913_022_08166_0 crossref_primary_10_3390_ijerph182413269 crossref_primary_10_3390_ijerph20075223 crossref_primary_10_1016_S1470_2045_23_00511_9 crossref_primary_10_1007_s12029_021_00752_5 crossref_primary_10_3389_fonc_2023_998940 |
ContentType | Journal Article |
Copyright | the authors; licensee ecancermedicalscience. the authors; licensee cancermedicalscience. 2021 |
Copyright_xml | – notice: the authors; licensee ecancermedicalscience. – notice: the authors; licensee cancermedicalscience. 2021 |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.3332/ecancer.2021.1180 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1754-6605 |
ExternalDocumentID | PMC7987492 33777173 10_3332_ecancer_2021_1180 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Department of Health grantid: NIHR300599 |
GroupedDBID | --- 29G 2WC 53G 5GY 5VS 7X7 8FI 8FJ AAYXX ABDBF ABUWG ACUHS ADBBV ADRAZ AEGXH AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 DIK EBD EBS EJD ESX FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE KQ8 M48 M~E OK1 OVT PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS UKHRP C1A NPM 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c399t-75d8d0261c035e7c28f71d5482bff9cfdf4e4108951ddab6fbd08bc87d6552533 |
IEDL.DBID | M48 |
ISSN | 1754-6605 |
IngestDate | Thu Aug 21 14:00:48 EDT 2025 Fri Sep 05 09:10:03 EDT 2025 Mon Jul 21 06:00:02 EDT 2025 Tue Jul 01 02:44:24 EDT 2025 Thu Apr 24 23:02:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 diagnosis cancer stage pandemic shift |
Language | English |
License | the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c399t-75d8d0261c035e7c28f71d5482bff9cfdf4e4108951ddab6fbd08bc87d6552533 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3332/ecancer.2021.1180 |
PMID | 33777173 |
PQID | 2506505903 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987492 proquest_miscellaneous_2506505903 pubmed_primary_33777173 crossref_citationtrail_10_3332_ecancer_2021_1180 crossref_primary_10_3332_ecancer_2021_1180 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-02-03 |
PublicationDateYYYYMMDD | 2021-02-03 |
PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Ecancermedicalscience |
PublicationTitleAlternate | Ecancermedicalscience |
PublicationYear | 2021 |
Publisher | Cancer Intelligence |
Publisher_xml | – name: Cancer Intelligence |
SSID | ssj0061925 |
Score | 2.337953 |
Snippet | One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1180 |
Title | The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33777173 https://www.proquest.com/docview/2506505903 https://pubmed.ncbi.nlm.nih.gov/PMC7987492 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB7iGIwvIX0racwWemgLcvVa7epQQltsTMGmlBp8E9I-SGiQndiB5Jafkf69_JLO6OHaremhZ-0sq_12mW9mdmYAXkuRGal87drcGDfSkruZNcqVPM44N4HgZYb3eBKPptGXGZ_tQdPeqt7A5U7TjvpJTa8u-jeXt6d44T-QxRmGwXujaIOouGfg96mkWQvaqJhiOuTjaB1UIFOBV4HN3WJd6IShEBSX3tZSf1HPP19Qbqik4SEc1FySfazAfwR7pngMnXEdLX8CCzwDrEqDZHPLGr8fQ4vfXZxt-rLZ-cbTxyV783B3j0ruhybX88Pdz7dsXjBkimzxO1mpoCmrf2N1cdblU5gOB98_j9y6w4KrkJisXMG11GSFKS_kRqhAWuFrNGKC3NpEWW0jE_meRBqmdZbHNteezJUUOuY8QKb4DPZxzeYF5X4HHEUocIgUTJvMUPAm8qVNDGX_OuA1O5qquvw4dcG4SNEMITzSGo-U8EgJDwferUUWVe2Nfw1-1cCU4g2hsEdWmPn1MkWShzSUJ17owPMKtvV0Dd4OiC1A1wOo-vb2l-L8rKzCLRIpoiQ4-m_JY-jS6ssn4OFL2F9dXZsTZDirvActMRM9aH8aTL5-65V-gl55ln8B2PoFZQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+national+non-pharmaceutical+interventions+%28%E2%80%98lockdowns%E2%80%99%29+on+the+presentation+of+cancer+patients&rft.jtitle=Ecancermedicalscience&rft.au=Purushotham%2C+Arnie&rft.au=Roberts%2C+Graham&rft.au=Haire%2C+Kate&rft.au=Dodkins%2C+Joanna&rft.date=2021-02-03&rft.pub=Cancer+Intelligence&rft.eissn=1754-6605&rft.volume=15&rft_id=info:doi/10.3332%2Fecancer.2021.1180&rft_id=info%3Apmid%2F33777173&rft.externalDocID=PMC7987492 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1754-6605&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1754-6605&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1754-6605&client=summon |